Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease
SOUTH SAN FRANCISCO, CA, May 23, 2023 – Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies...
SOUTH SAN FRANCISCO, CA, May 23, 2023 – Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies...
Phase 1 Clinical Trial Advances with First Subject Dosed in the E.U. and IND Accepted in the U.S...
Company’s first-in-class approach to targeting of signal regulatory proteins (SIRP) [...]
Drug discovery approach uncovers novel biology for treatments that can [...]
All of us know someone who has been affected by [...]